Anti-Infliximab Antibodies test for Serum Analysis | High-Sensitivity ECLIA Detection for Autoimmune Research & Drug Monitoring

Description

Anti-Infliximab Antibodies Test | High-Sensitivity ECLIA Detection for Autoimmune Patients in Dubai

If you’re being treated for Crohn’s disease, ulcerative colitis, rheumatoid arthritis, or ankylosing spondylitis with infliximab, but your symptoms are returning or worsening — the problem may not be your condition. It could be your body fighting the treatment itself.

The Anti-Infliximab Antibodies Test is a game-changing diagnostic tool that detects whether your immune system has developed antibodies against infliximab — a common reason for treatment failure. Using high-sensitivity Electrochemiluminescence Immunoassay (ECLIA) technology, this test delivers precise, reliable results to help your doctor optimize your therapy and get you back on track.

For patients in Dubai and across the UAE, this advanced test is now accessible through Lab Tests Dubai — offering fast, confidential, and accurate monitoring for biologic therapy patients.

Why You Need the Anti-Infliximab Antibodies Test

Infliximab (brand name Remicade® or biosimilars) is a powerful biologic drug used to suppress inflammation in autoimmune diseases. But over time, up to 40% of patients may develop anti-drug antibodies (ADAs) — immune proteins that neutralize infliximab and reduce its effectiveness.

This is where the Anti-Infliximab Antibodies Test becomes essential:

• 🔍 Identifies loss of response to infliximab
• 🛑 Prevents unnecessary dose escalation or premature switching of biologics
• 💡 Guides personalized treatment decisions (e.g., combo therapy with immunosuppressants)
• 🩺 Reduces risk of infusion reactions and disease flare-ups

If you’re investing in biologic therapy, you deserve to know it’s working. This test ensures your treatment stays effective — and your health stays on track.

Symptoms That Indicate You Need This Test

Don’t ignore these red flags — they could mean your body is rejecting infliximab:

• Return or worsening of symptoms (e.g., abdominal pain, joint swelling, diarrhea) after initial improvement
• Infusion reactions — fever, chills, rash, itching, or shortness of breath during or after infusion
• Loss of therapeutic effect over time (primary or secondary non-response)
• Frequent dose increases without sustained benefit
• Being on long-term infliximab therapy (especially without immunomodulators like azathioprine)

Even if you feel stable, routine monitoring of anti-infliximab antibodies can prevent future treatment failure — especially for chronic autoimmune conditions.

Natural Production: Why Your Body Might Attack Its Own Treatment

Infliximab is a chimeric monoclonal antibody — part human, part mouse — designed to block TNF-alpha, a key driver of inflammation in autoimmune diseases.

But your immune system may recognize the “mouse” part as foreign, triggering an immune response that produces anti-infliximab antibodies (ATI).

This immunogenicity can be influenced by:

• Genetic factors
• Dosing frequency and intervals
• Lack of concomitant immunosuppressive therapy (e.g., methotrexate or azathioprine)
• Intermittent treatment or missed doses

These antibodies can:

• Neutralize infliximab → reduced drug levels
• Accelerate drug clearance → shorter effectiveness
• Trigger immune complexes → infusion reactions

The Anti-Infliximab Antibodies Test detects these antibodies in serum, giving your doctor a clear view of your treatment response.

What Happens If Left Untreated?

Ignoring anti-infliximab antibodies can lead to serious consequences:

• Uncontrolled disease progression — increasing risk of bowel damage, joint deformity, or disability
• Severe infusion reactions — including anaphylaxis in rare cases
• Unnecessary switch to costlier biologics (e.g., adalimumab, vedolizumab, ustekinumab)
• Delayed diagnosis and prolonged suffering
• Increased hospitalizations and surgeries due to disease complications

Early detection through this test can save time, money, and health — helping you stay on the most effective treatment longer.

How to Prepare for the Test

Good news: no special preparation is needed. Here’s what to keep in mind:

✅ No fasting required
✅ Best timing: Test 1–2 weeks before your next infusion (or at least 14 days after the last dose) for accurate antibody detection
✅ Inform your doctor about all medications — especially immunosuppressants
✅ Avoid testing during active infusion reactions unless directed by your physician

A simple blood draw is all it takes. The serum sample is analyzed using ECLIA — one of the most sensitive and specific methods available.

Test Overview: Precision You Can Trust

FAQs About the Anti-Infliximab Antibodies Test

Q: Can I take this test while still on infliximab?
A: Yes — but timing matters. Test 14 days after your last infusion for the most accurate antibody reading.

Q: What does a positive result mean?
A: It means your body has developed antibodies against infliximab, which may explain reduced efficacy or infusion reactions. Your doctor may adjust your dose or add an immunosuppressant.

Q: Is this test covered by insurance?
A: Many insurance plans in Dubai cover therapeutic monitoring for biologics. Check with your provider or contact Lab Tests Dubai for assistance.

Q: Can I test at home?
A: Yes! Lab Tests Dubai offers home blood collection across Dubai and the UAE — no clinic visit needed.

Take Control of Your Treatment — Book Your Anti-Infliximab Antibodies Test Today!

You’ve taken the first step by starting infliximab therapy. Now, take the next step: make sure it’s working.

At Lab Tests Dubai, we provide accurate, confidential, and convenient access to the Anti-Infliximab Antibodies Test — so you and your doctor can make informed decisions about your care.